Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 32.14M | 29.43M | 18.51M | 12.40M | 8.40M | 5.43M |
Gross Profit | 27.51M | 25.33M | 15.91M | 10.14M | 7.21M | 3.24M |
EBITDA | -22.02M | -36.16M | -58.30M | -46.76M | -23.57M | -25.32M |
Net Income | -27.21M | -33.23M | -59.04M | -47.19M | -28.84M | -31.83M |
Balance Sheet | ||||||
Total Assets | 28.63M | 23.97M | 25.73M | 22.00M | 37.84M | 252.01M |
Cash, Cash Equivalents and Short-Term Investments | 13.00M | 8.53M | 11.78M | 9.41M | 30.30M | 4.49M |
Total Debt | 33.12M | 23.63M | 1.59M | 1.96M | 544.00K | 42.18M |
Total Liabilities | 62.99M | 49.87M | 51.66M | 198.32M | 167.44M | 23.50M |
Stockholders Equity | -34.37M | -25.89M | -25.94M | -176.33M | 30.90M | 228.52M |
Cash Flow | ||||||
Free Cash Flow | -35.51M | -41.19M | -51.17M | -33.10M | -23.95M | -1.22M |
Operating Cash Flow | -34.48M | -40.84M | -50.58M | -32.31M | -22.70M | -677.60K |
Investing Cash Flow | -993.00K | -345.00K | -2.12M | -1.79M | -2.26M | -250.00M |
Financing Cash Flow | 44.50M | 37.94M | 54.63M | 13.46M | 50.77M | 252.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $202.15M | ― | -92.33% | ― | 23.11% | 18.06% | |
51 Neutral | $7.91B | -0.36 | -41.71% | 2.23% | 23.45% | -1.86% | |
50 Neutral | $243.82M | ― | -87.65% | ― | 2.47% | 56.93% | |
47 Neutral | $257.32M | ― | 271.41% | ― | 45.50% | 53.07% | |
47 Neutral | $145.25M | ― | -350.22% | ― | 29.34% | -283.53% | |
44 Neutral | $38.18M | ― | -68.32% | ― | 93.07% | 13.25% | |
― | $84.68M | ― | ― | ― | ― |
On August 25, 2025, TriSalus Life Sciences, Inc. approved an increase in the annual compensation of their Chief Financial Officer, Mr. David Patience, from $450,000 to $550,000. Additionally, on August 28, 2025, the company granted Mr. Patience stock options to purchase 249,899 shares of common stock, contingent upon the company achieving or exceeding $75 million in revenue over a twelve-month period before the end of 2027.
TriSalus Life Sciences announced the completion of its exchange offer and consent solicitation for its Series A Convertible Preferred Stock, which expired on July 23, 2025. The company received consent from 98.82% of preferred stockholders to exchange their shares for common stock, allowing the adoption of a Preferred Stock Amendment that facilitates conversion of remaining preferred shares into common stock, thereby impacting its capital structure and potentially enhancing shareholder value.
On June 23, 2025, TriSalus Life Sciences announced the commencement of an exchange offer and consent solicitation for its Series A Convertible Preferred Stock. This initiative aims to streamline the company’s capital structure by allowing preferred shareholders to exchange their shares for common stock, thereby reducing potential dilution and improving transparency in equity value. Approximately 55% of preferred shareholders have agreed to the exchange and proposed amendments, which, if approved, will enable automatic conversion of remaining preferred shares into common stock. The offer is set to expire on July 23, 2025, and is contingent on certain conditions being met.
On June 12, 2025, TriSalus Life Sciences, Inc. held its Annual Meeting of Shareholders, where 73.2% of the total outstanding shares were represented. During the meeting, two directors were elected for three-year terms, and the appointment of Grant Thornton, LLP as the independent registered accounting firm for 2025 was ratified.